The reduction of ErbB2 levels following treatment with proteasome inhibitors has also recently been observed in breast cancer cell lines, where it has been ascribed to both transcriptional downregulation and the induction of lysosomal degradation mechanisms [58]. Here, ERBB2 is linked to breast cancer.